IN8bio Share Holder Equity 2020-2025 | INAB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

IN8bio share holder equity from 2020 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

IN8bio share holder equity from 2020 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$217.3B
Amgen (AMGN)	$160.8B
Gilead Sciences (GILD)	$136.6B
Vertex Pharmaceuticals (VRTX)	$120.6B
Bristol Myers Squibb (BMY)	$96B
CSL (CSLLY)	$78.5B
GSK (GSK)	$78.4B
Regeneron Pharmaceuticals (REGN)	$59.2B
Alnylam Pharmaceuticals (ALNY)	$42.1B
Argenex SE (ARGX)	$35.4B
BioNTech SE (BNTX)	$27B
Royalty Pharma (RPRX)	$20B
Insmed (INSM)	$19.8B
Biogen (BIIB)	$18.8B
Illumina (ILMN)	$15.3B
Genmab (GNMSF)	$14.2B
Genmab (GMAB)	$14B
Incyte (INCY)	$13.4B
Moderna (MRNA)	$12.4B
Exelixis (EXEL)	$12.2B
BioMarin Pharmaceutical (BMRN)	$11.2B
QIAGEN (QGEN)	$10.7B
Ascendis Pharma (ASND)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Exact Sciences (EXAS)	$10.1B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$8.1B
Roivant Sciences (ROIV)	$7.8B
Regencell Bioscience Holdings (RGC)	$7.6B